The CGM Adoption Gap Is Worse Than You Think

A new study found that continuous glucose monitors can cut healthcare costs by about 20% while also improving outcomes for insulin-dependent diabetes patients, largely by reducing hospitalizations and emergency department visits. Despite these benefits and broad insurance coverage, roughly 80% of eligible patients still are not using the technology — highlighting a significant adoption gap….

Read More

Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy

Omeros’s complement system drug Yartemlea is now FDA approved for treating a severe and potentially fatal complication of hematopoietic stem cell transplants. Our recap of other regulatory actions includes drug approvals in cancer, rare disease, and metabolic disorders. The post Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy appeared first on MedCity…

Read More